ImmunoPrecise Antibodies (TSXV: IPA) and its partner LiteVax BV jointly announced this morning that they have begun pre-clinical trials for their SARS-CoV-2 vaccine. The study is to take place at IRTA in Cataloni, Spain, focusing on the feasibility of the vaccine that the duo have jointly designed.
The design put together for the vaccine was based on data sets that ImmunoPrecise obtained from analysis of its SARS-CoV-2 therapeutic program. From this data, the company identified what it calls “spike protein variant vaccine candidates,” which were then combined with a vaccine adjuvant from LiteVax to establish a proposed formulation for a vaccine. The goal of the program was to design a vaccine with high efficacy and low adverse effects.
The pre clinical study will focus on the feasibility of this formulation, with the company looking to ultimately design a vaccine that requires a single low dose to be administered. The study is to assess the safety and tolerability of the formulations. Ex vivo assays are being conducted by the duo at the same time.
All study results expected to be compiled by November 2020. From here, ideal candidates will be narrowed down with which the company can move forward with.
ImmunoPrecise last traded at $2.37 on the TSX Venture.
Information for this analysis was found via Sedar and ImmunoPrecise Antibodies Ltd. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
